

PRIOR AUTHORIZATION REQUEST FORM
XOLAIR®

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department.

- For **Medical Pharmacy** please fax requests to 801-213-1547
- For **Retail Pharmacy** requests please fax requests to: 888-509-8142

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance: University of Utah Health Employees: 855-856-5690, Individual & Family Plans: 855-869-4769, Commercial Groups: 855-859-4892, MHC: 855-885-7695

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:	HCPCS Code:	

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Xolair® (omalizumab)

Dosing/Frequency: _____

Note: for the treatment of nasal polyps see Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)

If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
ASTHMA			
1. Is the member 6 years of age or older?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Is the prescribing physician an allergist, dermatologist, immunologist, or a pulmonologist?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Has the member shown a positive skin test or in vitro reactivity to a perennial aeroallergen?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Has the member been compliant on a high-dose inhaled corticosteroid with a long-acting inhaled beta-2-agonist for at least 5 months?	<input type="checkbox"/>	<input type="checkbox"/>	
5. Has the member had ≥2 acute exacerbations in a 12-month period requiring additional medical treatment (emergency department visits, hospitalizations, or frequent office visits)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
6. Does documentation include a current Asthma Control Test?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
7. Are the member's pre-treatment serum IgE levels ≥30 IU/mL and ≤700 IU/mL?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
8. Does documentation include a predicted FEV1 or PEF?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

CHRONIC IDOPATHIC URTICARIA (CIU)			
1. Is the member 12 years of age or older?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the provider performed a medical evaluation that rules out other possible causes of urticaria?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Has the member had a trial and failure of an H1-antihistamine used in combination with an H2-antihistamine?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Has the member had a trial and failure of an H1-antihistamine used in combination with a leukotriene receptor antagonist or cyclosporine?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
REAUTHORIZATION			
1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does clinical documentation show continued medical necessity and that the treatment has stabilized or improved the member's condition?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician's Signature:			

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request. ****

Policy PHARM-079
 Origination Date: 05/30/2015
 Reviewed/Revised Date: 01/18/2023
 Next Review Date: 01/18/2024
 Current Effective Date: 02/01/2023

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.